Animal models in translational medicine: Validation and prediction

Williams, 2013, Small nanobody drugs win big backing from pharma, Nat. Med., 19, 1355, 10.1038/nm1113-1355 Arrowsmith, 2011, Trial watch: phase II failures: 2008–2010, Nat. Rev. Drug Discov., 10, 328, 10.1038/nrd3439 Arrowsmith, 2011, Trial watch: phase III and submission failures: 2007–2010, Nat. Rev. Drug. Discov., 10, 87, 10.1038/nrd3375 Bouchlaka, 2013, Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy, J. Exp. Med., 210, 2223, 10.1084/jem.20131219 Hansen, 2006, TGN1412: scrutinizing preclinical trials of antibody-based medicines, Nature, 441, 282, 10.1038/441282a Stebbings, 2007, “Cytokine storm” in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics, J. Immunol., 179, 3325, 10.4049/jimmunol.179.5.3325 Attarwala, 2010, TGN1412: from discovery to disaster, J. Young Pharm., 2, 332, 10.4103/0975-1483.66810 Crabbe, 1999, Genetics of mouse behavior: interactions with laboratory environment, Science, 284, 1670, 10.1126/science.284.5420.1670 Richter, 2011, Effect of population heterogenization on the reproducibility of mouse behavior: a multi-laboratory study, PLoS One, 6, e16461, 10.1371/journal.pone.0016461 Wahlsten, 2003, Different data from different labs: lessons from studies of gene–environment interaction, J. Neurobiol., 54, 283, 10.1002/neu.10173 Hooijmans, 2011, Improving planning, design, reporting and scientific quality of animal experiments by using the Gold Standard Publication Checklist, in addition to the ARRIVE guidelines, Br. J. Pharmacol., 162, 1259, 10.1111/j.1476-5381.2010.01128.x Kilkenny, 2010, Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research, PLoS Biol., 8, e1000412, 10.1371/journal.pbio.1000412 Kilkenny, 2012, Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research, Osteoarthr. Cartil., 20, 256, 10.1016/j.joca.2012.02.010 Rice, 2008, Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards, Pain, 139, 243, 10.1016/j.pain.2008.08.017 Lamberty, 2000, Absence of negative impact of levetiracetam on cognitive function and memory in normal and amygdala-kindled rats, Epilepsy Behav., 1, 333, 10.1006/ebeh.2000.0098 Weyer, 1999, Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes – an update, Diabetes Metab., 25, 11 Sams-Dodd, 2006, Strategies to optimize the validity of disease models in the drug discovery process, Drug Discov. Today, 11, 355, 10.1016/j.drudis.2006.02.005 Derscheid, 2012, Perinatal lamb model of respiratory syncytial virus (RSV) infection, Viruses, 4, 2359, 10.3390/v4102359 Villenave, 2012, In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo, Proc. Natl. Acad. Sci. USA, 109, 5040, 10.1073/pnas.1110203109 Ito, 2012, Current advances in humanized mouse models, Cell. Mol. Immunol., 9, 208, 10.1038/cmi.2012.2 Siolas, 2013, Patient-derived tumor xenografts: transforming clinical samples into mouse models, Cancer Res., 73, 5315, 10.1158/0008-5472.CAN-13-1069 Pitts, 2010, Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development, Clin. Cancer Res., 16, 3193, 10.1158/1078-0432.CCR-09-3191 Tentler, 2012, Patient-derived tumour xenografts as models for oncology drug development, Nat. Rev. Clin. Oncol., 9, 338, 10.1038/nrclinonc.2012.61 Fiebig, 2004, Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery, Eur. J. Cancer, 40, 802, 10.1016/j.ejca.2004.01.009 Kerbel, 2003, Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved, Cancer Biol. Ther., 2, S134 Hidalgo, 2011, A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer, Mol. Cancer Ther., 10, 1311, 10.1158/1535-7163.MCT-11-0233 Weroha, 2014, Tumorgrafts as in vivo surrogates for women with ovarian cancer, Clin. Cancer Res., 20, 1288, 10.1158/1078-0432.CCR-13-2611 Shultz, 2012, Humanized mice for immune system investigation: progress, promise and challenges, Nat. Rev. Immunol., 12, 786, 10.1038/nri3311 Zhou, 2014, Humanized NOD-SCID IL2rg(-/-) mice as a preclinical model for cancer research and its potential use for individualized cancer therapies, Cancer Lett., 344, 13, 10.1016/j.canlet.2013.10.015 Danner, 2011, Expression of HLA class II molecules in humanized NOD.Rag1KO.IL2RgcKO mice is critical for development and function of human T and B cells, PLoS One, 6, e19826, 10.1371/journal.pone.0019826 Shultz, 2010, Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice, Proc. Natl. Acad. Sci. USA, 107, 13022, 10.1073/pnas.1000475107 Singh, 2014, Minocycline attenuates HIV-1 infection and suppresses chronic immune activation in humanized NOD/LtsZ-scidIL-2Rgamma mice, Immunology, 142, 562, 10.1111/imm.12246 Abate-Daga, 2014, A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer, Hum. Gene Ther., 10.1089/hum.2013.209 Brown, 2009, A novel approach to the use of animals in studies of pain: validation of the canine brief pain inventory in canine bone cancer, Pain Med., 10, 133, 10.1111/j.1526-4637.2008.00513.x Guest, 2013, Proteomics: improving biomarker translation to modern medicine?, Genome Med., 5, 17, 10.1186/gm421 Arendt-Nielsen, 2007, Human experimental pain models in drug development: translational pain research, Curr. Opin. Investig. Drugs, 8, 41 Olesen, 2012, Human experimental pain models for assessing the therapeutic efficacy of analgesic drugs, Pharmacol. Rev., 64, 722, 10.1124/pr.111.005447 Maxwell, 2008, Application of a systems biology approach to skin allergy risk assessment, Altern. Lab. Anim., 36, 521, 10.1177/026119290803600510 Schmidt, 2013, Mechanistic systems modeling to guide drug discovery and development, Drug Discov. Today, 18, 116, 10.1016/j.drudis.2012.09.003 Geerts, 2013, Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development, J. Pharmacokinet. Pharmacodyn., 40, 257, 10.1007/s10928-013-9297-1 Konstantinopoulos, 2013, Current status and evolution of preclinical drug development models of epithelial ovarian cancer, Front. Oncol., 3, 296, 10.3389/fonc.2013.00296 Moro, 2012, Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells, J. Biomed. Biotechnol., 2012, 568567, 10.1155/2012/568567